Short communication Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes
|
|
- William Stephens
- 6 years ago
- Views:
Transcription
1 Antiviral Therapy 14: Short communication Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF2_AG subtypes Almoustapha-Issiaka Maïga 1, Isabelle Malet 1 *, Cathia Soulie 1, Anne Derache 1, Victoria Koita 2, Bahia Amellal 1, Luba Tchertanov 3, Olivier Delelis 3, Laurence Morand-Joubert 4, Jean-François Mouscadet 3, Robert Murphy 5, Mamadou Cissé 2, Christine Katlama 5, Vincent Calvez 1 and Anne-Genevieve Marcelin 1 1 Department of Virology, Pitié-Salpêtrière Hospital, AP-HP, EA 2387, Université Pierre et Marie Curie, Paris, France 2 Centre d Ecoute, de Soins, d Animation et de Conseil, Bamako, Republic of Mali 3 LBPA, CNRS, Ecole Normale Supérieure de Cachan, Cachan, France 4 Department of Bacteriology-Virology, Saint-Antoine Hospital, AP-HP, Université Pierre et Marie Curie, Paris, France 5 Department of Infectious Diseases, Pitié-Salpêtrière Hospital, AP-HP, Université Pierre et Marie Curie, Paris, France *Corresponding author: isabelle.malet@psl.aphp.fr These authors made an equal contribution to this work Background: HIV type-1 (HIV-1) integrase (IN) inhibitor resistance is the consequence of mutations that are selected in the viral IN gene targeted by antiretroviral drugs, such as raltegravir (RAL) and elvitegravir (EVG). The genetic barrier, defined as the number of viral mutations required to overcome the drug-selective pressure, is one of the important factors in the development of drug resistance. The genetic barrier for IN inhibitor resistance was compared between HIV-1 subtype B and HIV-1 subtype CRF2_AG, which is highly prevalent in West Africa and becoming more frequent in developed countries. Methods: IN nucleotide sequences from 73 HIV-1 subtype B and 77 HIV-1 subtype CRF2_AG antiretroviral-naive patients were examined at 19 IN amino acid positions implicated in RAL and EVG resistance. Results: The majority (14/19) of the studied positions showed a high degree of conservation of the predominant codon sequences leading to a similar genetic barrier between subtypes B and CRF2_AG. Nevertheless, at positions 14 and 151, the variability between subtypes affected the genetic barrier for the mutations G14C, G14S and V151I with a higher genetic barrier being calculated for subtype CRF2_AG. Conclusions: The major IN mutations E92Q, Q148K/R/H, N155H and E157Q (implicated in the resistance of IN inhibitors RAL and EVG) are highly conserved between subtypes B and CRF2_AG and display a similar genetic barrier. However, subtype CRF2_AG showed a higher genetic barrier to acquire mutations G14S, G14C and V151I as compared with subtype B, which could play a role in the resistance to RAL and/or EVG. Introduction Retroviral integrase (IN) is responsible for an essential step in HIV type-1 (HIV-1) replication involving the integration of retrovirus DNA into the host cell DNA. IN catalyses two reactions: 3 -end processing during which the terminal GpT dinucleotide is cleaved from the 3 -end of each long terminal repeat, producing CpA 3 -hydroxyl ends [1] and strand transfer in which both newly exposed 3 extremities of the viral DNA are covalently linked, by a one-step transesterification, into the host genome [2,3]. Raltegravir (RAL; MK-518) and elvitegravir (EVG; JTK-33/GS-9137) are members of a new class of HIV-1 inhibitors that block HIV-1 IN activity by interfering with the strand transfer stage [4,5]. Recently, IN resistance mutations have been described for RAL and EVG. Concerning RAL failure in vivo, it has been generally associated with two different genetic pathways: N155H associated with the secondary mutations L74M, E92Q, T97A, V151I and G163R or Q148K/R/H. RAL failure in vitro has been associated with the secondary mutations G14S/A and E138K. Other mutations could play a role in the resistance and/or failure, including Y143R/C plus L74A/I, E92Q, T97A, E157Q, I3M and S23R [6 9]. Concerning EVG resistance in vitro, the primary mutations T66I and E92K appearing with several secondary mutations H51Y, F121Y, S147G, S153Y, E157Q and R263K 9 International Medical Press
2 AI Maïga et al. have been described [1]. In vivo, two profiles have been more frequently described: E92Q with N155H and N155H with E138K, S147G, Q148R, G14S/C or Q148R/H [11]. The genetic barrier, defined as the number of viral mutations required to overcome the drug-selective pressure, is an important factor in the development of resistance. It has been shown that the rate of protease inhibitor (PI), nucleoside reverse transcriptase inhibitor (NRTI) and non-nrti (NNRTI) resistance development on the basis of the calculated genetic barrier might be similar for different HIV-1 subtypes. Nevertheless, several positions involving minor protease substitutions have shown a higher genetic barrier for some individual non-b subtypes, whereas other minor protease substitutions might influence resistance pathways [12]. HIV-1 subtype B is mainly found in the Americas, Europe and Australia, and subtype CRF2_AG, highly prevalent in West Africa, is becoming more frequent in developed countries [13 15]. Because of the lack of information concerning IN inhibitors and the prevalence of subtypes B and CRF2_AG, it is important to explore how the variability between subtypes B and CRF2_AG could affect IN resistance. Indeed, previous results have suggested some differences between subtypes B and CRF2_AG IN in a three-dimensional model [16]. The aim of this study was to explore the IN genetic barrier for evolution of RAL and EVG resistance substitutions. The variability at the nucleotide level between subtypes B and CRF2_AG could have a significant effect on the genetic barrier for RAL and EVG resistance. To explore the effect of this variability, IN nucleotide sequences from 73 HIV-1 subtype B and 77 HIV-1 subtype CRF2_AG antiretroviral (ARV)-naive patients were examined at 19 IN amino acid positions corresponding to 27 substitutions implicated in RAL and EVG resistance. Methods A total of 15 plasma samples were collected from patients who were diagnosed with HIV-1 infection in two clinical centres between 3 and 5 (CESAC, Bamako, the Republic of Mali and Pitié-Salpêtrière Hospital, Paris, France). All of these 15 patients had never received any ARV therapy. Subtype determination was on the basis of the reverse transcriptase and protease coding regions. Among the 15 patients, 73 were infected with HIV-1 subtype CRF2_AG and 77 with HIV-1 subtype B. A 1,86 base pair fragment encompassing the entire IN gene was amplified, sequenced and analysed as previously described [8]. The codons were evaluated for evolution from wild type by comparison with the HxB2 reference sequence in the 15 studied patients to all described RAL and EVG resistance-associated substitutions. The calculations used in this study were performed as described by van de Vijver et al. [12]. In summary, transitions (ts; A G or C T) occurred on average 2.5 more frequently than transversions (tv; A C, A T, C G, G T). The smallest number of ts (scored as 1) and/ or tv (scored as 2.5) required for evolution to RAL or EVG resistance-associated substitutions were used to calculate the genetic barrier. Results A total of 19 IN amino acid positions (51, 66, 74, 92, 97, 121, 138, 14, 143, 147, 148, 151, 153, 155, 157, 163, 3, 23 and 263) related to 27 IN resistance mutations were studied to explore the genetic barrier for RAL and EVG resistance. The global analyses of the 15 nucleotide sequences (73 from subtype B and 77 from subtype CRF2_AG) at the 19 studied positions showed 42 wild-type codons encoding for the expected wild-type amino acids determined on the basis of the HxB2 reference sequence and 12 codons reflecting a polymorphism at the amino acid level corresponding with L/I/M74, T/A97, V/I151, E/Q157, G/E/Q/N163, I/M/Q3 and S/N23 (the expected wild-type amino acid is represented in bold; Table 1). At each position, we always found a predominant codon that represented 74% of the population except at position 92 for subtype B, where the codons and accounted for 63% and 37%, respectively. At four positions, the predominant codons were different depending on the subtype: /GGC for subtype CRF2_AG/ subtype B for G14, AGC/AGT for S147, GTG/GTA for V151 and GGG/ for G163 (Table 1). The 42 wild-type codons present at the 19 positions described above were analysed. For each codon, we evaluated the number of ts and/or tv required for a drug resistance-associated substitution. A total of 27 amino acid substitutions implicated in RAL and/or EVG resistance were analysed and all the codons corresponding to a drug resistance substitution were evaluated (Table 1). Then, to calculate the genetic barrier from each wildtype codon, the mutated codon that allows the smallest number of ts and/or tv was retained (minimal score column in Table 1). Most of the predominant codons were remarkably conserved among subtypes B and CRF2_AG as the same prevalent codon was found in 14/19 positions (51, 66, 74, 97, 121, 138, 143, 148, 153, 155, 157, 3, 23 and 263); thus, variable scores of 1, 2, 2.5 or 3.5 were calculated according to the amino acid substitution considered, independently of the subtype (Figure 1). Different predominant codons between subtypes B and CRF2_AG were observed in 5/19 positions (92, International Medical Press
3 The genetic barrier of HIV-1 integrase Table 1. Evaluation of the number of transitions and transversions required to obtain codons encoding for mutated amino acids and the calculated minimal score for genetic barrier analyses IN codon Codon, % position Subsitution a Codon Subtype B Subtype CRF2_AG Mutational resistance codon b Minimal score c 51 H51Y CAT 99 TAT 1ts TAC 2ts 1 CAC 1 2ts 1ts 1 66 T66I ACA ATT 1ts, 1tv ATC 1ts, 1tv 1ts 1 ACC 3 1 2ts 1ts 1ts, 1tv 1 ACT 3 1ts 2ts 1ts, 1tv 1 74 L74A CTG GCT 1ts, 2tv GCC 1ts, 2tv GCA 2ts, 1tv GCG 1ts, 1tv 3.5 CTA 4 5 1ts, 2tv 1ts, 2tv 1ts, 1tv 2ts, 1tv 3.5 TTG 4 3 1ts, 2tv 1ts, 2tv 2ts, 1tv 1ts, 1tv 3.5 TTA 6 1ts, 2tv 1ts, 2tv 1ts, 1tv 2ts, 1tv 3.5 (I74A) 4 8 3ts 2ts, 1tv 2ts 3ts 2 (M74A) 1 4 2ts, 1tv 2ts, 1tv 3ts 2ts 2 L74I CTG ATT 2tv ATC 2tv 1ts, 1tv 3.5 CTA 4 5 2tv 2tv 1tv 2.5 TTG 4 3 2tv 2tv 2tv 5 TTA 6 2tv 2tv 1tv 2.5 (I74) 4 8 1tv 1tv (M74I) 1 4 1tv 1tv 1ts 1 L74M CTG tv 2.5 CTA 4 5 1ts, 1tv 3.5 TTG 4 3 1tv 2.5 TTA 6 1ts, 1tv 3.5 (I74M) 4 8 1ts 1 (M74) E92Q tv CAG 1ts, 1tv ts, 1tv 1tv 2.5 E92K AAA 1ts AAG 2ts ts 1ts 1 97 T97A ACA 96 GCT 1ts, 1tv GCC 1ts, 1tv GCA 1ts GCG 2ts 1 ACG 1 1ts, 1tv 1ts, 1tv 2ts 1ts 1 (A97) GCA 3 1tv 1tv 1ts 121 F121Y TTC 88 TAT 1ts, 1tv TAC 1tv 2.5 TTT 12 1tv 1ts, 1tv E138K 99 AAA 1ts AAG 2ts 1 1 2ts 1ts 1 14 G14S 9 99 AGT 1ts, 1tv AGC 1ts, 1tv TCT 3tv TCC 3tv TCG 1ts, 2tv TCA 2tv 3.5 GGC 77 2ts 1ts 1ts, 2tv 2tv 3tv 3tv 1 GGT ts 2ts 2tv 1ts, 2tv 3tv 3tv 1 G14A 9 99 GCT 2tv GCC 2tv GCA 1tv GCG 1ts, 1tv 2.5 GGC 77 1ts, 1tv 1tv 2tv 2tv 2.5 Evaluation of the number of transitions (ts) and transversions (tv) required to obtain codons encoding for mutated amino acids implicated in raltegravir and elvitegravir resistance, and the calculation of the minimal score to evaluate the genetic barrier for each codon. a The substitution is specified in brackets when the amino acid is different from the HxB2 wild-type amino acid and is underlined when it already corresponds to the expected mutant amino acid. b The number of ts and tv selected to calculate the minimal score are in italics and bold. c The calculated score is dependent on the number of ts and tv; 1 ts is scored as 1 and 1 tv is scored as 2.5. IN, integrase. Antiviral Therapy
4 AI Maïga et al. Table 1. Continued IN codon Codon, % position Subsitution a Codon Subtype B Subtype CRF2_AG Mutational resistance codon b Minimal score c GGT tv 1ts, 1tv 2tv 2tv 2.5 G14C 9 99 TGT 2tv TGC 2tv 5 GGC 77 1ts, 1tv 1tv 2.5 GGT tv 1ts, 1tv Y143C TAC 99 TGT 2ts TGC 1ts 1 TAT 1 1ts 2ts 1 Y143R TAC 99 CGT 3ts CGC 2ts CGA 2ts, 1tv CGG 2ts, 1tv AGA 1ts, 2tv AGG 1ts, 2tv 2 TAT 1 2ts 3ts 2ts, 1tv 2ts, 1tv 1ts, 2tv 1ts, 2tv S147G AGT GGT 1ts GGG 1ts, 1tv 1ts, 1tv GGC 2ts 1 AGC ts 1ts, 1tv 1ts, 1tv 1ts Q148H CAT 1tv CAC 1tv 2.5 CAG 4 1 1tv 1tv 2.5 Q148K AAA 1tv AAG 1ts, 1tv 2.5 CAG 4 1 1ts, 1tv 1tv 2.5 Q148R CGT 1ts, 1tv CGC 1ts, 1tv CGA 1ts CGG 2ts AGA 1ts, 1tv AGG 2ts, 1tv 1 CAG 4 1 1ts, 1tv 1ts, 1tv 2ts 1ts 2ts, 1tv 1ts, 1tv V151I GTA ATT 1ts, 1tv ATC 1ts, 1tv 1ts 1 GTG 88 1ts, 1tv 1ts, 1tv 2ts 2 GTC 1 2ts 1ts 1ts, 1tv 1 (I151) 1 1tv 1tv 153 S153Y TCT TAT 1tv TAC 1ts, 1tv 2.5 TCC 7 6 1ts, 1tv 1tv 2.5 TCA 1 2tv 2tv N155H AAT CAT 1tv CAC 1ts, 1tv 2.5 AAC 1 4 1ts, 1tv 1tv E157Q tv CAG 1ts, 1tv ts, 1tv 1tv 2.5 (Q157) 1 5 1ts 163 G163R GGG CGT 2tv CGC 2tv CGA 1ts, 1tv CGG 1tv AGA 2ts AGG 1ts ts, 1tv 2tv 1tv 1ts, 1tv 1ts 2ts 1 (E163R) 4 1ts, 2tv 1ts, 2tv 1ts, 1tv 2ts, 1tv 2ts 3ts 2 (Q163R) 1 1 1ts, 1tv 1ts, 1tv 1ts 2ts 1ts, 1tv 2ts, 1tv 1 (E163R) 1 1ts, 2tv 1ts, 2tv 2ts, 1tv 1ts, 1tv 3ts 2ts 2 (N163R) AAT 1 1ts, 1tv 2ts, 1tv 1ts, 2tv 1ts, 2tv 1ts, 1tv 1ts, 1tv I3M ts 1 (Q3M) 1 1ts, 2tv 6 (M3) S23R AGC 9 CGT 1ts, 1tv CGC 1tv CGA 2tv CGG 2tv AGA 1tv AGG 1tv 2.5 (N23R) AAC 1 2ts, 1tv 1ts, 1tv 1ts, 2tv 1ts, 2tv 1ts, 1tv 1ts, 1tv R263K AGA AAA 1ts AAG 2ts 1 AGG 4 3 2ts 1ts International Medical Press
5 The genetic barrier of HIV-1 integrase Figure 1. Comparison of the integrase genetic barriers for the evolution of RAL and EVG resistance substitutions between HIV-1 subtypes B and CRF2_AG Subtype B 6 4 Predominant codons, % Subtype CRF2_AG Subtype B 4 6 H51Y 6 4 CAT CAC ACA ACC ACT T66I CTG CTA TTG TTA L74A CTG CTA TTG TTA L74I CTG CTA TTG TTA L74M ACA GCA ACG TTC TTT GGC GGT GGC GGT GGC GGT E92Q E92K T97A F121Y E138K G14S G14A G14C Subtype CRF2_AG 4 6 TAC TAT TAC TAT AGT AGC CAG CAG CAG GTA GTG GTC Y143C Y143R S147G Q148H Q148K Q148R V15II TCT TCC TCA AAT AAC S153Y N155H E157Q GGG AAT G163R RAL and EVG resistance-associated substitutions AGC AAC AGA AGG 13M S23R R263K Calculated score Comparison of the genetic barrier in the integrase (in relation to raltegravir [RAL] and elvitegravir [EVG] resistance mutations) between HIV type-1 (HIV-1) subtypes B and CRF2_AG. The frequency of each codon is represented by bars (up for subtype B and down for subtype CRF2_AG) at positions related to RAL and EVG resistance mutations. The minimal calculated score for each corresponding codon is represented by a colour code. Mutations with different calculated genetic barriers between subytpes B and CRF2_AG are underlined. Antiviral Therapy
6 AI Maïga et al. 14, 147, 151 and 163). Only at positions 14 and 151 did these differences have an effect on the calculated genetic barrier (1 versus 3.5 for G14S, 2.5 versus 5 for G14C and 1 versus 2 for V151I, respectively, for subtype B versus subtype CRF2_AG; Figure 1). Discussion The genetic barrier is an important determinant for the development of resistance and could be influenced by the existence of HIV-1 variability at the nucleotide level among the different HIV-1 subtypes. In this study, HIV-1 IN sequences isolated from subtypes B and CRF2_AG ARV-naive patients were studied at 19 amino acid positions related to RAL and EVG resistance-associated substitutions and used to calculate the genetic barrier. The majority of the studied positions (14/19) responsible for RAL and/or EVG resistance, particularly concerning the primary substitutions E92Q, Q148H/K/R, N155H and E157Q, showed a high degree of conservation of the predominant codon sequences, thus suggesting a similar genetic barrier between subtypes B and CRF2_AG. It seemed that the IN inhibitors mostly target sites that are functionally important as they are similar across the two studied subtypes B and CRF2_AG. Concordant results were described in a study concerning PI, NRTI and NNRTI resistance-associated positions where it has been shown that the calculated genetic barrier for nine studied HIV-1 subtypes were the same with just a few positions concerning minor protease substitutions described [12]. Among the five positions with predominant codons that differed between subtypes B and CRF2_AG (5/19), substitutions related to positions 92, 147 and 163 did not lead to a different genetic barrier, whereas polymorphisms at positions 14 and 151 led to higher scores for subtype CRF2_AG for the three mutations G14C, G14S and V151I. In the same way, in the study concerning the calculated genetic barrier for PI, NRTI and NNRTI described above, few positions that differentiated subtypes have shown a higher genetic barrier for non-b subtypes than for subtype B [12]. Concerning the resistance to RAL, most of the studies have shown that Q148K/R/H is always associated with G14S during RAL failure [6,8,1]. The fact that the genetic barrier calculated for G14S is higher for subtype CRF2_AG than B could possibly suggest that it would be more difficult for subtype CRF2_AG to become resistant to RAL or perhaps it will preferentially fail via the N155H pathway. In some patients, natural codons encoding for amino acids implicated in the RAL primary resistance (L74I/M, T97A, V151I, E157Q and I3M) were described, suggesting that resistance to IN inhibitors could be natural or could occur faster in these patients. In conclusion, the major IN mutations E92Q, Q148K/R/H, N155H and E157Q, implicated in the resistance of IN inhibitors RAL and EVG are very well conserved between the two more frequent subtypes in France, B and CRF2_AG, and they display a similar genetic barrier. However, subtype CRF2_AG showed a higher genetic barrier to acquire mutations G14S, G14C and V151I as compared with subtype B and this should be further investigated in clinical practice. Acknowledgements This work was presented at the 15th ICASA, 3 7 December 8, Dakar, Sénégal as an oral presentation. This work was supported by Sidaction and the ANRS (the French National Agency for AIDS research). Disclosure statement The authors declare no competing interests. References 1. Engelman A, Mizuuchi K, Craigie R. HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer. Cell 1991; 67: Brown PO, Bowerman B, Varmus HE, Bishop JM. Retroviral integration: structure of the initial covalent product and its precursor, and a role for the viral IN protein. Proc Natl Acad Sci U S A 1989; 86: Ellison V, Abrams H, Roe T, Brown P. Human immunodeficiency virus integration in a cell-free system. J Virol 199; 64: Lataillade M, Kozal MJ. The hunt for HIV-1 integrase inhibitors. AIDS Patient Care STDS 6; : Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov 5; 4: Cooper D, Gatell J, Rockstroh C, et al. Results of BENCHMRK-1, a phase III study evaluating the efficacy and safety of MK-518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. 14th Conference of Retroviruses and Opportunistic Infections February 7, Los Angeles, CA, USA. Abstract 15aLB. 7. Goethals O, Clayton R, Wagemans E, et al. Resistance mutations in HIV-1 integrase selected with raltegravir or elvitegravir confer reduced susceptibility to a diverse panel of integrase inhibitors. XVII International HIV Drug Resistance Workshop June 8, Sitges, Spain. Abstract Malet I, Delelis O, Valantin MA, et al. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother 8; 52: Steigbigel R, Kumar P, Eron J, et al. Results of BENCHMRK-2, a phase III study evaluating the efficacy and safety of MK-518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. 14th Conference of Retroviruses and Opportunistic Infections February 7, Los Angeles, CA, USA. 1. Jones G, Ledford R, Yu F, et al. Resistance profile of HIV-1 mutants in vitro selected by the HIV-1 integrase inhibitor, GS-9137 (JTK-33). 14th Conference of Retroviruses and Opportunistic Infections February 7, Los Angeles, CA, USA International Medical Press
7 The genetic barrier of HIV-1 integrase 11. McColl D, Fransen E, Gupta S, et al. Resistance and crossresistance to first generation integrase inhibitors: insights from a Phase II study of elvitegravir (GS-9137). XVI international HIV Drug Resistance Workshop June 7, Barbados, West Indies. 12. van de Vijver DA, Wensing AM, Angarano G, et al. The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr 6; 41: Derache A, Traore O, Koita V, et al. Genetic diversity and drug resistance mutations in HIV type 1 from untreated patients in Bamako, Mali. Antivir Ther 7; 12: Descamps D, Chaix ML, Andre P, et al. French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 1 2. J Acquir Immune Defic Syndr 5; 38: Wensing AM, van de Vijver DA, Angarano G, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 5; 192: Malet I, Soulie C, Tchertanov L, et al. Structural effects of amino acid variations between B and CRF2_AG HIV-1 integrases. J Med Virol 8; : Accepted for publication 13 October 8 Antiviral Therapy
c Tuj1(-) apoptotic live 1 DIV 2 DIV 1 DIV 2 DIV Tuj1(+) Tuj1/GFP/DAPI Tuj1 DAPI GFP
Supplementary Figure 1 Establishment of the gain- and loss-of-function experiments and cell survival assays. a Relative expression of mature mir-484 30 20 10 0 **** **** NCP mir- 484P NCP mir- 484P b Relative
More informationSupplementary Table 3. 3 UTR primer sequences. Primer sequences used to amplify and clone the 3 UTR of each indicated gene are listed.
Supplemental Figure 1. DLKI-DIO3 mirna/mrna complementarity. Complementarity between the indicated DLK1-DIO3 cluster mirnas and the UTR of SOX2, SOX9, HIF1A, ZEB1, ZEB2, STAT3 and CDH1with mirsvr and PhastCons
More informationSupplementary Document
Supplementary Document 1. Supplementary Table legends 2. Supplementary Figure legends 3. Supplementary Tables 4. Supplementary Figures 5. Supplementary References 1. Supplementary Table legends Suppl.
More informationSupplemental Data. Shin et al. Plant Cell. (2012) /tpc YFP N
MYC YFP N PIF5 YFP C N-TIC TIC Supplemental Data. Shin et al. Plant Cell. ()..5/tpc..95 Supplemental Figure. TIC interacts with MYC in the nucleus. Bimolecular fluorescence complementation assay using
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Sherman SI, Wirth LJ, Droz J-P, et al. Motesanib diphosphate
More informationBIOLOGY 621 Identification of the Snorks
Name: Date: Block: BIOLOGY 621 Identification of the Snorks INTRODUCTION: In this simulation activity, you will examine the DNA sequence of a fictitious organism - the Snork. Snorks were discovered on
More informationa) Primary cultures derived from the pancreas of an 11-week-old Pdx1-Cre; K-MADM-p53
1 2 3 4 5 6 7 8 9 10 Supplementary Figure 1. Induction of p53 LOH by MADM. a) Primary cultures derived from the pancreas of an 11-week-old Pdx1-Cre; K-MADM-p53 mouse revealed increased p53 KO/KO (green,
More informationSupplementary Figure 1 a
Supplementary Figure a Normalized expression/tbp (A.U.).6... Trip-br transcripts Trans Trans Trans b..5. Trip-br Ctrl LPS Normalized expression/tbp (A.U.) c Trip-br transcripts. adipocytes.... Trans Trans
More informationSupplementary Figure 1. ROS induces rapid Sod1 nuclear localization in a dosagedependent manner. WT yeast cells (SZy1051) were treated with 4NQO at
Supplementary Figure 1. ROS induces rapid Sod1 nuclear localization in a dosagedependent manner. WT yeast cells (SZy1051) were treated with 4NQO at different concentrations for 30 min and analyzed for
More informationTable S1. Oligonucleotides used for the in-house RT-PCR assays targeting the M, H7 or N9. Assay (s) Target Name Sequence (5 3 ) Comments
SUPPLEMENTAL INFORMATION 2 3 Table S. Oligonucleotides used for the in-house RT-PCR assays targeting the M, H7 or N9 genes. Assay (s) Target Name Sequence (5 3 ) Comments CDC M InfA Forward (NS), CDC M
More informationSupplementary Figure 1 MicroRNA expression in human synovial fibroblasts from different locations. MicroRNA, which were identified by RNAseq as most
Supplementary Figure 1 MicroRNA expression in human synovial fibroblasts from different locations. MicroRNA, which were identified by RNAseq as most differentially expressed between human synovial fibroblasts
More informationNature Structural & Molecular Biology: doi: /nsmb Supplementary Figure 1
Supplementary Figure 1 U1 inhibition causes a shift of RNA-seq reads from exons to introns. (a) Evidence for the high purity of 4-shU-labeled RNAs used for RNA-seq. HeLa cells transfected with control
More informationResistance to Integrase Strand Transfer Inhibitors
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Resistance to Integrase Strand Transfer Inhibitors David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases
More informationFigure S1. Analysis of genomic and cdna sequences of the targeted regions in WT-KI and
Figure S1. Analysis of genomic and sequences of the targeted regions in and indicated mutant KI cells, with WT and corresponding mutant sequences underlined. (A) cells; (B) K21E-KI cells; (C) D33A-KI cells;
More informationSupplementary Materials
Supplementary Materials 1 Supplementary Table 1. List of primers used for quantitative PCR analysis. Gene name Gene symbol Accession IDs Sequence range Product Primer sequences size (bp) β-actin Actb gi
More informationToluidin-Staining of mast cells Ear tissue was fixed with Carnoy (60% ethanol, 30% chloroform, 10% acetic acid) overnight at 4 C, afterwards
Toluidin-Staining of mast cells Ear tissue was fixed with Carnoy (60% ethanol, 30% chloroform, 10% acetic acid) overnight at 4 C, afterwards incubated in 100 % ethanol overnight at 4 C and embedded in
More informationCitation for published version (APA): Oosterveer, M. H. (2009). Control of metabolic flux by nutrient sensors Groningen: s.n.
University of Groningen Control of metabolic flux by nutrient sensors Oosterveer, Maaike IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it.
More informationAbbreviations: P- paraffin-embedded section; C, cryosection; Bio-SA, biotin-streptavidin-conjugated fluorescein amplification.
Supplementary Table 1. Sequence of primers for real time PCR. Gene Forward primer Reverse primer S25 5 -GTG GTC CAC ACT ACT CTC TGA GTT TC-3 5 - GAC TTT CCG GCA TCC TTC TTC-3 Mafa cds 5 -CTT CAG CAA GGA
More informationSupplementary Figures
Supplementary Figures Supplementary Figure 1. H3F3B expression in lung cancer. a. Comparison of H3F3B expression in relapsed and non-relapsed lung cancer patients. b. Prognosis of two groups of lung cancer
More informationNature Immunology: doi: /ni.3836
Supplementary Figure 1 Recombinant LIGHT-VTP induces pericyte contractility and endothelial cell activation. (a) Western blot showing purification steps for full length murine LIGHT-VTP (CGKRK) protein:
More information*To whom correspondence should be addressed. This PDF file includes:
www.sciencemag.org/cgi/content/full/science.1212182/dc1 Supporting Online Material for Partial Retraction to Detection of an Infectious Retrovirus, XMRV, in Blood Cells of Patients with Chronic Fatigue
More informationwww.lessonplansinc.com Topic: Protein Synthesis - Sentence Activity Summary: Students will simulate transcription and translation by building a sentence/polypeptide from words/amino acids. Goals & Objectives:
More informationNucleotide Sequence of the Australian Bluetongue Virus Serotype 1 RNA Segment 10
J. gen. Virol. (1988), 69, 945-949. Printed in Great Britain 945 Key words: BTV/genome segment lo/nucleotide sequence Nucleotide Sequence of the Australian Bluetongue Virus Serotype 1 RNA Segment 10 By
More informationBeta Thalassemia Case Study Introduction to Bioinformatics
Beta Thalassemia Case Study Sami Khuri Department of Computer Science San José State University San José, California, USA sami.khuri@sjsu.edu www.cs.sjsu.edu/faculty/khuri Outline v Hemoglobin v Alpha
More informationTransmission of integrase resistance HIV
Transmission of integrase resistance HIV Charles Boucher, MD, PhD Clinical Virology, Dept. Viroscience, Erasmus Medical Center, Erasmus Universiy, The Netherlands Major resistance mutations (Stanford)
More informationCulture Density (OD600) 0.1. Culture Density (OD600) Culture Density (OD600) Culture Density (OD600) Culture Density (OD600)
A. B. C. D. E. PA JSRI JSRI 2 PA DSAM DSAM 2 DSAM 3 PA LNAP LNAP 2 LNAP 3 PAO Fcor Fcor 2 Fcor 3 PAO Wtho Wtho 2 Wtho 3 Wtho 4 DTSB Low Iron 2 4 6 8 2 4 6 8 2 22 DTSB Low Iron 2 4 6 8 2 4 6 8 2 22 DTSB
More informationDetection of 549 new HLA alleles in potential stem cell donors from the United States, Poland and Germany
HLA ISSN 2059-2302 BRIEF COMMUNICATION Detection of 549 new HLA alleles in potential stem cell donors from the United States, Poland and Germany C. J. Hernández-Frederick 1, N. Cereb 2,A.S.Giani 1, J.
More informationCD31 5'-AGA GAC GGT CTT GTC GCA GT-3' 5 ' -TAC TGG GCT TCG AGA GCA GT-3'
Table S1. The primer sets used for real-time RT-PCR analysis. Gene Forward Reverse VEGF PDGFB TGF-β MCP-1 5'-GTT GCA GCA TGA ATC TGA GG-3' 5'-GGA GAC TCT TCG AGG AGC ACT T-3' 5'-GAA TCA GGC ATC GAG AGA
More informationMutations to Integrase Inhibitors in real life
Mutations to Integrase Inhibitors in real life González-Domenech CM, Viciana I, Sena Corrales G, Delgado M, De la Torre J, Torres Tortosa M, Téllez F, Jarilla F, Clavijo E, Santos J BACKGROUND INSTI Block
More informationSupplementary Figure 1a
Supplementary Figure 1a Hours: E-cadherin TGF-β On TGF-β Off 0 12 24 36 48 24 48 72 Vimentin βactin Fig. S1a. Treatment of AML12 cells with TGF-β induces EMT. Treatment of AML12 cells with TGF-β results
More informationResistance to inhibitors of the human immunodeficiency virus type 1 integration
Resistance to inhibitors of the human immunodeficiency virus type 1 integration REVIEW ARTICLE ABSTRACT This review will summarize the role of integrase in HIV-1 infection, the mechanism of integrase inhibitors
More informationLezione 10. Sommario. Bioinformatica. Lezione 10: Sintesi proteica Synthesis of proteins Central dogma: DNA makes RNA makes proteins Genetic code
Lezione 10 Bioinformatica Mauro Ceccanti e Alberto Paoluzzi Lezione 10: Sintesi proteica Synthesis of proteins Dip. Informatica e Automazione Università Roma Tre Dip. Medicina Clinica Università La Sapienza
More informationSupplementary Table 2. Conserved regulatory elements in the promoters of CD36.
Supplementary Table 1. RT-qPCR primers for CD3, PPARg and CEBP. Assay Forward Primer Reverse Primer 1A CAT TTG TGG CCT TGT GCT CTT TGA TGA GTC ACA GAA AGA ATC AAT TC 1B AGG AAA TGA ACT GAT GAG TCA CAG
More informationSupplementary Figure 1
Supplementary Figure 1 Supplementary Figure 1. Lats1/2 deleted ihbs and ihps showed decreased transcripts of hepatocyte related genes (a and b) Western blots (a) and recombination PCR (b) of control and
More informationSupplemental Information. Th17 Lymphocytes Induce Neuronal. Cell Death in a Human ipsc-based. Model of Parkinson's Disease
Cell Stem Cell, Volume 23 Supplemental Information Th17 Lymphocytes Induce Neuronal Cell Death in a Human ipsc-based Model of Parkinson's Disease Annika Sommer, Franz Maxreiter, Florian Krach, Tanja Fadler,
More informationSUPPLEMENTARY INFORMATION
doi: 10.1038/nature05883 SUPPLEMENTARY INFORMATION Supplemental Figure 1 Prostaglandin agonists and antagonists alter runx1/cmyb expression. a-e, Embryos were exposed to (b) PGE2 and (c) PGI2 (20μM) and
More informationAstaxanthin prevents and reverses diet-induced insulin resistance and. steatohepatitis in mice: A comparison with vitamin E
Supplementary Information Astaxanthin prevents and reverses diet-induced insulin resistance and steatohepatitis in mice: A comparison with vitamin E Yinhua Ni, 1,2 Mayumi Nagashimada, 1 Fen Zhuge, 1 Lili
More informationBeta Thalassemia Sami Khuri Department of Computer Science San José State University Spring 2015
Bioinformatics in Medical Product Development SMPD 287 Three Beta Thalassemia Sami Khuri Department of Computer Science San José State University Hemoglobin Outline Anatomy of a gene Hemoglobinopathies
More informationCharacterizing intra-host influenza virus populations to predict emergence
Characterizing intra-host influenza virus populations to predict emergence June 12, 2012 Forum on Microbial Threats Washington, DC Elodie Ghedin Center for Vaccine Research Dept. Computational & Systems
More informationDescription of Supplementary Files. File Name: Supplementary Information Description: Supplementary Figures and Supplementary Tables
Description of Supplementary Files File Name: Supplementary Information Description: Supplementary Figures and Supplementary Tables Supplementary Figure 1: (A), HCT116 IDH1-WT and IDH1-R132H cells were
More informationIntroduction to HIV Drug Resistance. Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School
Introduction to HIV Drug Resistance Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School Objectives 1. Describe the epidemiology of HIV drug resistance in sub-saharan Africa. 2.
More informationSupplementary Figure 1
Metastatic melanoma Primary melanoma Healthy human skin Supplementary Figure 1 CD22 IgG4 Supplementary Figure 1: Immunohisochemical analysis of CD22+ (left) and IgG4 (right), cells (shown in red and indicated
More informationJournal of Cell Science Supplementary information. Arl8b +/- Arl8b -/- Inset B. electron density. genotype
J. Cell Sci. : doi:.4/jcs.59: Supplementary information E9. A Arl8b /- Arl8b -/- Arl8b Arl8b non-specific band Gapdh Tbp E7.5 HE Inset B D Control al am hf C E Arl8b -/- al am hf E8.5 F low middle high
More informationCross-talk between mineralocorticoid and angiotensin II signaling for cardiac
ONLINE SUPPLEMENT TO Crosstalk between mineralocorticoid and angiotensin II signaling for cardiac remodeling An Di ZHANG,,3, Aurelie NGUYEN DINH CAT*,,3, Christelle SOUKASEUM *,,3, Brigitte ESCOUBET, 4,
More informationA smart acid nanosystem for ultrasensitive. live cell mrna imaging by the target-triggered intracellular self-assembly
Electronic Supplementary Material (ESI) for Chemical Science. This journal is The Royal Society of Chemistry 2017 A smart ZnO@polydopamine-nucleic acid nanosystem for ultrasensitive live cell mrna imaging
More informationA basic helix loop helix transcription factor controls cell growth
A basic helix loop helix transcription factor controls cell growth and size in root hairs Keke Yi 1,2, Benoît Menand 1,3, Elizabeth Bell 1, Liam Dolan 1,4 Supplementary note Low soil phosphate availability
More informationActualités en virologie Paris, le 6 juillet 2011 Journée scientifique de Solthis
Actualités en virologie Paris, le 6 juillet 2011 Journée scientifique de Solthis Pr Vincent CALVEZ MD, PhD Dpt of Virology Pitié-Salpêtrière Hospital Paris, France Transmitted Drug Resistance in Low and
More informationMutation Screening and Association Studies of the Human UCP 3 Gene in Normoglycemic and NIDDM Morbidly Obese Patients
Mutation Screening and Association Studies of the Human UCP 3 Gene in Normoglycemic and NIDDM Morbidly Obese Patients Shuichi OTABE, Karine CLEMENT, Séverine DUBOIS, Frederic LEPRETRE, Veronique PELLOUX,
More informationAbstract #8 15th EU Meeting on HIV & Hepatitis (7-9 June 2017)
Epidemiological study of Doravirine associated resistance mutations in HIV-1- infected treatment-naïve patients from two large databases in France and Italy Anne-Genevieve Marcelin, Maria Mercedes Santoro,
More informationHistory (August 2010) Therapy for Experienced Patients. History (September 2010) History (November 2010) 12/2/11
(August 2010) Therapy for Experienced Patients Hiroyu Hatano, MD, MHS Assistant Professor of Medicine University of California San Francisco Medical Management of AIDS December 2011 42M HIV (CD4=450, VL=6250,
More informationPhylogenetic analysis of human and chicken importins. Only five of six importins were studied because
Supplementary Figure S1 Phylogenetic analysis of human and chicken importins. Only five of six importins were studied because importin-α6 was shown to be testis-specific. Human and chicken importin protein
More informationSUPPORTING INFORMATION
SUPPORTING INFORMATION Biology is different in small volumes: endogenous signals shape phenotype of primary hepatocytes cultured in microfluidic channels Amranul Haque, Pantea Gheibi, Yandong Gao, Elena
More informationPrinciples of HIV Drug Resistance: Resistance to New Drug Classes. Mark A Wainberg McGill University AIDS Centre Montreal, Quebec, Canada
Principles of HIV Drug Resistance: Resistance to New Drug Classes Mark A Wainberg McGill University AIDS Centre Montreal, Quebec, Canada Why Is It Important to Understand HIV Drug Resistance? 1. Resistance
More informationIntegrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection
Journal of Antimicrobial Chemotherapy Advance Access published December 9, 2009 J Antimicrob Chemother doi:10.1093/jac/dkp423 Integrase variability and susceptibility to HIV integrase inhibitors: impact
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationDoes Resistance Still Matter? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Does Resistance Still Matter? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosure The speaker serves as a consultant to, and has received
More informationResistance Characteristics of Integrase Inhibitors
Resistance Characteristics of Integrase Inhibitors Madrid, November 2016 Jonathan M Schapiro, MD National Hemophilia Center, Israel Stanford University School of Medicine, USA Disclaimer Presentation includes
More informationSupporting Information
Supporting Information Malapeira et al. 10.1073/pnas.1217022110 SI Materials and Methods Plant Material and Growth Conditions. A. thaliana seedlings were stratified at 4 C in the dark for 3 d on Murashige
More informationUpdate on HIV Drug Resistance. Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Update on HIV Drug Resistance Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Learning Objectives Upon completion of this presentation, learners
More informationSupplemental Information. Cancer-Associated Fibroblasts Neutralize. the Anti-tumor Effect of CSF1 Receptor Blockade
Cancer Cell, Volume 32 Supplemental Information Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors Vinit Kumar, Laxminarasimha
More informationSupporting Information. Mutational analysis of a phenazine biosynthetic gene cluster in
Supporting Information for Mutational analysis of a phenazine biosynthetic gene cluster in Streptomyces anulatus 9663 Orwah Saleh 1, Katrin Flinspach 1, Lucia Westrich 1, Andreas Kulik 2, Bertolt Gust
More informationIntegrase strand-transfer inhibitors primary resistance in patients with acute/recent HIV infection
Integrase strand-transfer inhibitors primary resistance in patients with acute/recent HIV infection Juan Ambrosioni, David Nicolás, Christian Manzardo, Fernando Agüero, José Luis Blanco, Maria del Mar
More informationPRINCIPLES and TRENDS in MANAGEMENT of HIV DISEASE: PROBLEMS OF DRUG RESISTANCE in VIRUSES of DIFFERENT SUBTYPES
PRINCIPLES and TRENDS in MANAGEMENT of HIV DISEASE: PROBLEMS OF DRUG RESISTANCE in VIRUSES of DIFFERENT SUBTYPES Mark A. Wainberg McGill University AIDS Centre Jewish General Hospital Montreal, Quebec,
More informationIntegration Solutions
Integration Solutions (1) a) With no active glycosyltransferase of either type, an ii individual would not be able to add any sugars to the O form of the lipopolysaccharide. Thus, the only lipopolysaccharide
More informationL I F E S C I E N C E S
1a L I F E S C I E N C E S 5 -UUA AUA UUC GAA AGC UGC AUC GAA AAC UGU GAA UCA-3 5 -TTA ATA TTC GAA AGC TGC ATC GAA AAC TGT GAA TCA-3 3 -AAT TAT AAG CTT TCG ACG TAG CTT TTG ACA CTT AGT-5 OCTOBER 31, 2006
More informationRelationship of the APOA5/A4/C3/A1 gene cluster and APOB gene polymorphisms with dyslipidemia
elationship of the APOA5/A4/C3/A1 gene cluster and APOB gene polymorphisms with dyslipidemia H.J. Ou 1, G. Huang 2, W. Liu 3, X.L. Ma 2, Y. Wei 4, T. Zhou 5 and Z.M. Pan 3 1 Department of Neurology, The
More informationSUPPLEMENTARY DATA. Supplementary Table 1. Primer sequences for qrt-pcr
Supplementary Table 1. Primer sequences for qrt-pcr Gene PRDM16 UCP1 PGC1α Dio2 Elovl3 Cidea Cox8b PPARγ AP2 mttfam CyCs Nampt NRF1 16s-rRNA Hexokinase 2, intron 9 β-actin Primer Sequences 5'-CCA CCA GCG
More informationVirological failure to Protease inhibitors in Monotherapy is linked to the presence of signature mutations in Gag without changes in HIV-1 replication
Virological failure to Protease inhibitors in Monotherapy is linked to the presence of signature mutations in Gag without changes in HIV-1 replication Oscar Blanch-Lombarte Rome, 7-9 June, 2017 European
More informationINTEGRASE INHIBITOR (INI) RESISTANCE IN HIV- POSITIVE PATIENTS UNDERGOING ROUTINE TESTING
INTEGRASE INHIBITOR (INI) RESISTANCE IN HIV- POSITIVE PATIENTS UNDERGOING ROUTINE TESTING Dr. Danni Kirwan ID/Microbiology SpR St. George s Hospital, London ARV initiation in treatment-naïve patients BHIVA,
More informationBaseline clinical characteristics for the 81 CMML patients Routine diagnostic testing and statistical analyses... 3
Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 72.8% of Chronic Myelomonocytic Leukemia (CMML) by Detecting Frequent Alterations in TET2, CBL, RAS, and
More informationSupplementary Figure 1
Supplementary Figure 1 3 3 3 1 1 Bregma -1.6mm 3 : Bregma Ref) Http://www.mbl.org/atlas165/atlas165_start.html Bregma -.18mm Supplementary Figure 1 Schematic representation of the utilized brain slice
More informationShort communication Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance
Short communication Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance Max Lataillade 1 *, Jennifer Chiarella 1 and Michael J Kozal 1,2 1 Yale
More informationIt takes more than just a single target
It takes more than just a single target As the challenges you face evolve... HIV mutates No HIV-1 mutation can be considered to be neutral 1 Growing evidence indicates all HIV subtypes may be prone to
More informationThe E138A substitution in HIV-1 reverse transcriptase decreases in vitro. susceptibility to emtricitabine as indicated by competitive fitness assays
AAC Accepts, published online ahead of print on 13 January 2014 Antimicrob. Agents Chemother. doi:10.1128/aac.02114-13 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 The E138A
More informationHIV integrase variability and genetic barrier in antiretroviral naïve and experienced patients
RESEARCH Open Access HIV integrase variability and genetic barrier in antiretroviral naïve and experienced patients Antonio Piralla 1, Stefania Paolucci 1, Roberto Gulminetti 2, Giuditta Comolli 1,3 and
More informationCIRCRESAHA/2004/098145/R1 - ONLINE 1. Validation by Semi-quantitative Real-Time Reverse Transcription PCR
CIRCRESAHA/2004/098145/R1 - ONLINE 1 Expanded Materials and Methods Validation by Semi-quantitative Real-Time Reverse Transcription PCR Expression patterns of 13 genes (Online Table 2), selected with respect
More informationAcquired INSTI Resistance. Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Acquired INSTI Resistance Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker has received consulting honoraria, speaker
More informationof Integrase Inhibitors
Resistance Characteristics of Integrase Inhibitors Dr Charlotte CHARPENTIER Laboratoire de Virologie Hôpital Bichat-Claude Bernard INSERM UMR 1137- IAME Université Paris Diderot Plan 1 st generation: Raltegravir
More informationNomenclature What is in a name? My name Joseˊ Jimenez = Bill Dana John L.C. Savony = Frank Fontaine
Nomenclature What is in a name? My name Joseˊ Jimenez = Bill Dana John L.C. Savony = Frank Fontaine Three categories of Amyloid Terms 1. Amyloidologists, Amyloid Centers, Researchers official nomenclature
More informationMutation analysis of a Chinese family with oculocutaneous albinism
/, 2016, Vol. 7, (No. 51), pp: 84981-84988 Mutation analysis of a Chinese family with oculocutaneous albinism Xiong Wang 1, Yaowu Zhu 1, Na Shen 1, Jing Peng 1, Chunyu Wang 1, Haiyi Liu 2, Yanjun Lu 1
More informationARV Mode of Action. Mode of Action. Mode of Action NRTI. Immunopaedia.org.za
ARV Mode of Action Mode of Action Mode of Action - NRTI Mode of Action - NNRTI Mode of Action - Protease Inhibitors Mode of Action - Integrase inhibitor Mode of Action - Entry Inhibitors Mode of Action
More informationmodified dye uptake assay including formazan test EC 90 not tested plaque reduction assay
Sauerbrei A, Bohn-Wippert K, Kaspar M, Krumbholz A, Karrasch M, Zell R. 2015. Database on natural polymorphisms and resistance-related non-synonymous mutations in thymidine kinase and DNA polymerase genes
More informationHIV Drug Resistance: An Overview
Human Journals Review Article October 2015 Vol.:1, Issue:1 All rights are reserved by Suraj Narayan Mali et al. HIV Drug Resistance: An Overview Keywords: HIV drug resistance mechanism, Antiretroviral
More informationFinding protein sites where resistance has evolved
Finding protein sites where resistance has evolved The amino acid (Ka) and synonymous (Ks) substitution rates Please sit in row K or forward The Berlin patient: first person cured of HIV Contracted HIV
More informationSUPPLEMENTARY INFORMATION
SUPPLEMENTARY INFORMATION doi:10.1038/nature10743 Supplementary Figures and Legends Supplementary Figure 1. CYP17A1 (red boxes) lies at the intersection of steroid hormone biosynthetic pathways. CYP17A1
More informationLoyer, et al. microrna-21 contributes to NASH Suppl 1/15
Loyer, et al. microrna-21 contributes to NASH Suppl 1/15 SUPPLEMENTARY MATERIAL: Liver MicroRNA-21 is Overexpressed in Non Alcoholic Steatohepatitis and Contributes to the Disease in Experimental Models
More informationIsolation and Genetic Characterization of New Reassortant H3N1 Swine Influenza Virus from Pigs in the Midwestern United States
JOURNAL OF VIROLOGY, May 2006, p. 5092 5096 Vol. 80, No. 10 0022-538X/06/$08.00 0 doi:10.1128/jvi.80.10.5092 5096.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved. Isolation
More informationTetR repressor-based bioreporters for the detection of doxycycline using Escherichia
Supplementary materials TetR repressor-based bioreporters for the detection of doxycycline using Escherichia coli and Acinetobacter oleivorans Hyerim Hong and Woojun Park * Department of Environmental
More informationGenotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir
J Antimicrob Chemother ; : doi:.9/jac/dkp77 Advance publication 7 January Genotypic/phenotypic patterns of HIV- integrase resistance to raltegravir Filippo Canducci *, Maria Chiara Marinozzi, Michela Sampaolo,,
More informationEnhanced detection and serotyping of Streptococcus pneumoniae using multiplex polymerase chain reaction
Original article http://dx.doi.org/10.3345/kjp.2012.55.11.424 Korean J Pediatr 2012;55(11):424-429 eissn 1738-1061 pissn 2092-7258 Enhanced detection and serotyping of Streptococcus pneumoniae using multiplex
More informationHIV-1 Subtypes: An Overview. Anna Maria Geretti Royal Free Hospital
HIV-1 Subtypes: An Overview Anna Maria Geretti Royal Free Hospital Group M Subtypes A (1, 2, 3) B C D F (1, 2) G H J K Mechanisms of HIV-1 genetic diversification Point mutations RT error rate: ~1 per
More informationBHP 2-7 and Nthy-ori 3-1 cells were grown in RPMI1640 medium (Hyclone) supplemented with 10% fetal bovine serum (Gibco), 2mM L-glutamine, and 100 U/mL
1 2 3 4 Materials and Methods Cell culture BHP 2-7 and Nthy-ori 3-1 cells were grown in RPMI1640 medium (Hyclone) 5 supplemented with 10% fetal bovine serum (Gibco), 2mM L-glutamine, and 100 U/mL 6 penicillin-streptomycin.
More informationIntroduction to the Impact of Resistance in Hepatitis C
Introduction to the Impact of Resistance in Hepatitis C Sponsored by AbbVie 2/1/2017 Presented by Sammy Saab, MD, MPH, FACG, AGAF, FAASLD February 1 st, 2017 1 AbbVie disclosures This is an Abbvie sponsored
More informationIsolate Sexual Idiomorph Species
SUPLEMENTARY TABLE 1. Isolate identification, sexual idiomorph and species of each isolate used for MAT locus distribution in Paracoccidioides species. Isolate Sexual Idiomorph Species Pb01 MAT1-1 P. lutzii
More informationEvaluation and Management of Virologic Failure
National HIV Curriculum PDF created November 3, 2018, 12:26 am Evaluation and Management of Virologic Failure This is a PDF version of the following document: Section 1: Antiretroviral Therapy Topic 5:
More informationSUPPLEMENTARY INFORMATION
SUPPLEMENTARY INFORMATION Autonomous Multistep Organic Synthesis in a Single Isothermal Solution Mediated by a DNA Walker Yu He and David R. Liu* Supplementary Methods General Methods. DNA oligonucleotides
More informationFormylpeptide receptor2 contributes to colon epithelial homeostasis, inflammation, and tumorigenesis
Supplementary Data Formylpeptide receptor2 contributes to colon epithelial homeostasis, inflammation, and tumorigenesis Keqiang Chen, Mingyong Liu, Ying Liu, Teizo Yoshimura, Wei Shen, Yingying Le, Scott
More informationMechanistic and functional insights into fatty acid activation in Mycobacterium tuberculosis SUPPLEMENTARY INFORMATION
Mechanistic and functional insights into fatty acid activation in Mycobacterium tuberculosis Pooja Arora 1, Aneesh Goyal 2, Vivek T atarajan 1, Eerappa Rajakumara 2, Priyanka Verma 1, Radhika Gupta 3,
More informationSUPPLEMENTAL METHODS Cell culture RNA extraction and analysis Immunohistochemical analysis and laser capture microdissection (LCM)
SUPPLEMENTAL METHODS Cell culture Human peripheral blood mononuclear cells were isolated from healthy donors by Ficoll density gradient centrifugation. Monocyte differentiation to resting macrophages ()
More information